April 11th, 2012
Study Evaluates Losartan Efficacy in Heart Failure
The angiotensin II-receptor blocker (ARB) losartan has labored under the perception that it is not as potent as other ARBs, and some evidence has suggested that it may not confer the same clinical benefits as other ARBs in heart failure patients. In a paper from Denmark published in JAMA, Henrik Svanström and colleagues performed a country-wide registry study in which they compared heart failure patients who were new users of losartan and candesartan.
Overall there were no significant differences in mortality between the two groups:
- Adjusted hazard ratio (HR) for losartan: 1.10, CI 0.96-1.25
- Low-dose losartan: HR 2.79, CI 2.19-3.55
- Medium-dose losartan: HR 1.39, CI, 1.11-1.73
- High-dose losartan: HR 0.71, CI, 0.50-1.00